Unknown

Dataset Information

CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.


ABSTRACT: Artificial receptors designed for adoptive immune therapies need to absolve dual functions: antigen recognition and abilities to trigger the lytic machinery of reprogrammed effector T lymphocytes. In this way, CAR-T cells deliver their cytotoxic hit to cancer cells expressing targeted tumor antigens, bypassing the limitation of HLA-restricted antigen recognition. Expanding technologies have proposed a wide repertoire of soluble and cellular "immunological weapons" to kill tumor cells; they include monoclonal antibodies recognizing tumor associated antigens on tumor cells and immune cell checkpoint inhibition receptors expressed on tumor specific T cells. Moreover, a wide range of formidable chimeric antigen receptors diversely conceived to sustain quality, strength and duration of signals

SUBMITTER: Sacchetti B 

PROVIDER: S-EPMC6514830 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature